Progenics acquires AZEDRAź (iobenguane I 131) radiopharmaceutical manufacturing facility
Progenics announced that it has acquired the Somerset, NJ manufacturing facility for AZEDRAź (iobenguane I 131) for cash consideration of $8.0 million. AZEDRA is the first and only FDA-approved radiopharmaceutical indicated for the treatment of pheochromocytoma and paraganglioma, ultra-rare cancers. February 11, 2019